Bringing science and development together through original news and analysis

Rift Valley fever vaccine heads for human trials
  • Rift Valley fever vaccine heads for human trials

Copyright: Robin Hammond/Panos

Speed read

  • Multispecies vaccine proved safe and eliminated virus in livestock

  • Next steps are human clinical trials and livestock field trials

  • It would be first vaccine to protect humans from disease

Shares
A new single-dose vaccine against Rift Valley fever has shown promising results in livestock, paving the way for human trials later this year, researchers say.

Rift Valley fever — a mosquito-borne viral disease present in Africa and the Arabian Peninsula — mostly affects animals, but can also infect humans. At the moment, no vaccines are available for humans and “those widely used in livestock have major safety concerns”, scientists write in a paper published last month (5 February) in Scientific Reports.

“A large section of the genetic material in the chimpanzee adenovirus ChAd was deleted to prevent the virus from being able to reproduce in human or animals after vaccination.”

George Warimwe, University of Oxford’s Jenner Institute, United Kingdom


In trials carried out in Kenya and Saudi Arabia, they tested an experimental vaccine that could one day be used to treat both humans and livestock. It uses parts of a chimpanzee virus with a record of safe use in human and livestock vaccinations.

The vaccine also incorporates a gene for a Rift Valley fever virus protein, which is “recognised by the animal or human immune system, causing antibodies to be produced against the Rift Valley fever virus”, explains lead author George Warimwe, an immunologist at the University of Oxford’s Jenner Institute in the United Kingdom.

The researchers found that the vaccine is safe for humans and animals, and eliminated the Rift Valley fever virus from the blood.

“A large section of the genetic material in the chimpanzee adenovirus ChAd was deleted to prevent the virus from being able to reproduce in human or animals after vaccination, and the immune system rapidly clears the virus,” says Warimwe, who tested the vaccine in sheep, goats and cattle in Kenya.

In Saudi Arabia, the research team also tested the vaccine on camels, “which can transmit the virus to other animals without showing symptoms, and the results were positive with no side effects”, says coauthor Ayman El-Behiry, a microbiologist at Qassim University there.

Ahmed El-Sanousi, a virologist at Cairo University’s faculty of veterinary medicine in Egypt, praises the new vaccine for its low cost, ease of preparation and high safety.
“The new technique can be used in an average laboratory, unlike [other vaccines] that need a highly equipped lab,” he says, adding that a similar approach could be used to develop vaccines against other infectious diseases such as malaria, tuberculosis and HIV/AIDS.

The next step will be human clinical trials later this year, Warimwe says. The team will also test the vaccine in livestock field trials in East Africa and seek licensing for veterinary use. Results from both trials are expected by the end of 2017, Warimwe adds.

References

George M. Warimwe and others Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever (Scientific Reports, 5 February 2016)
Republish
We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.